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Off label prescribing—that is, prescribing a medicine for an
indication not listed in the product information, or for a patient
outside the approved age range—is common, but controversial.
On the one hand, it can promote clinical innovation and provide
options for patients for whom no other alternatives are available.
On the other hand, it can be harmful, because safety data are
often lacking; it impedes the generation of good quality
evidence, and it comes at a considerable cost to patients,
governments, and other payers.1 2
In this paper, we discuss the off-label use of recombinant factor
VIIa (rFVIIa) for major haemorrhage, to provide insights into
the forces driving off-label prescribing and to illustrate some
of the inevitable limits to evidence based medicine.
Clinical disagreement
rFVIIa is a procoagulant approved for patients with haemophilia
and antibody inhibitors against factor VIII or factor IX. Recent
studies, however, have shown that up to 97% of rFVIIa
prescribing is off-label, with the intent to stop bleeding in
conditions such as intracranial haemorrhage, cardiac surgery,
trauma, liver transplantation, and prostatectomy.3 It is estimated
that rFVIIa was used in more than 70 000 hospital cases in the
United States between 2000 and 2008. During this period its
off-label use increased 140-fold, while use for haemophilia in
hospitals increased less than fourfold.3Although some evidence
indicates that rFVIIa might reduce blood loss and transfusion
requirements in patients without haemophilia, evidence has also
been accumulating that it does not reduce mortality, might be
associated with an increased rate of thromboembolic events
including stroke and coronary occlusion,4-9 and costs
approximately $10 000 (£6400, €7400) per patient.10
According to the principles of evidence based medicine, which
allow off-label prescribing only when “adequately data driven,”10
these findings should lead to a rational reassessment of the place
of rFVIIa in clinical practice, and to a restriction of its off-label
uses. Indeed, the authors of a recent Cochrane review concluded
that use of rFVIIa outside its current licensed indications should
be restricted to clinical trials,8 and it has even been argued that
legal action might be taken against those who continue to
promote or use rFVIIa inappropriately.10
But these conclusions have met with some resistance. For
example, in response to a systematic review11 and editorial10
published in a recent issue of the Annals of Internal Medicine,
Karkouti and Levi12 countered that:
“When presentedwith a patient who continues to bleed
despite administration of all available therapies,
clinicians have 2 choices: keep administering the
standard interventions that have failed to work in that
patient, or administer a novel therapy like rFVIIa . . .
even if the safety data from existing randomized
trials… do apply . . . this is probably dwarfed by the
risk for allowing blood loss to continue unabated . . .
All procoagulant agents have the risk for potential
adverse responses, but their individualized risk-benefit
profile is largely dependent on the clinical context.”
Why use rFVIIa without supportive data?
If we are to resolve this impasse (and others like it) we need to
understand why clinicians might continue using rFVIIa for the
treatment of haemorrhage, even when faced with accumulating
evidence that it does not reduce mortality and could cause harm.
A number of intersecting epidemiological, psychological, social,
and ethical reasons may explain the dramatic growth in off-label
use of rFVIIa despite no substantial evidence of long term
benefit.
First, some possible outcomes of using off-label rFVIIa might
not be adequately described (or valued) by the existing data.
Although rFVIIa does not seem to reduce overall mortality, this
does not rule out the possibility that it might be of use—at least
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for some patients, in some situations—by reducing blood loss,
transfusion requirements, re-operation, or even mortality. The
pursuit of such outcomes might be sufficient to drive practice.
Second, outcome data are not the only kind of evidence that
clinicians find compelling; potent ancillary logics might prompt
them to use rFVIIa for haemorrhage. The drug has a clearly
established mechanism of action and is well known to reduce
bleeding in some situations where little else works, so to use it
in other patients with bleeding seems theoretically and clinically
logical.
Third is the problem of observed association—clinicians may
have seen patients stop bleeding after being given rFVIIa, and
this may lead to a judgment about its efficacy. Although these
clinical observations might be accurate, they may represent
simply a temporal relationship rather than a causal one.
Fourth are powerful moral and psychological forces. The “rule
of rescue” describes the imperative people feel to rescue
identifiable individuals facing avoidable death.13 14 In such
situations, evidence and rational decision making can be
overwhelmed by the need to act, irrespective of whether the
intervention has a logical basis:
“There is a fact about the human psyche that will
inevitably trump the utilitarian rationality that is
implicit in cost-effectiveness analysis: people cannot
stand idly by when an identified person’s life is visibly
threatened if rescue measures are available.”15
From amoral, cultural, and psychological standpoint, clinicians
may feel compelled to prescribe rFVIIa in order to do everything
in their power for the patient.
The psychological response to active bleeding is also a powerful
force. Blood loss has primal associations16 and the duty of care
arises as much from the primitive response as from moral and
legal obligation. Whatever epidemiologists might say, the
emotional challenge posed by bleeding is powerful, and the
imperative to do something—particularly where not much time
is available for reflection—remains strong.
Another likely psychological force is anticipated regret.17
Because rFVIIa is a relatively safe agent, despite the small risks
of stroke or coronary occlusion, clinicians might believe that
there is nothing to lose when someone has a life threatening
haemorrhage. Those looking after a patient with massive
bleeding might anticipate regret at a person in their care dying,
and this feeling might dominate both acknowledgment of the
risks of thrombosis and the evidence that the intervention is
unlikely to reduce mortality.
Clinicians may also prescribe rFVIIa off-label simply because
they crave autonomy,10 or control over their own
practice—including determination of what counts as evidence.
This is one of the many well known explanations for the
sometimes slow clinical uptake of evidence.
Taken together, these factors can dominate our beliefs and
commitments in the face of contrary evidence. Action, reason,
and even truth, it seems, can be warranted by desperate need.
In situations of peer review, a doctor might express doubts about
the value of off-label rFVIIa, or admit that the evidence is
convincingly against it. In the heat of an emergency, however,
the notion that it might be worth trying is likely to break through.
The same reasoning could well apply to the patient and his or
her family: “If there is any chance that the drug will help, then
let us use it.” Even sceptical doctors might say the same if asked
how they would feel if they themselves were bleeding to death.
Finally, there is the power of commercial opportunism. It is
well documented that some drug companies promote the use of
their products off-label to encourage patient demand and clinical
familiarity, thereby increasing sales.18 Much of the unjustified
support for rFVIIa comes from the medical profession, but the
manufacturers have done little to counsel doctors about the poor
record of off-label use (and have recently settled a civil lawsuit
for improper marketing of rFVIIa for $25m [£16m, €20m]).19
This is unsurprising given that condoning such use is highly
profitable—particularly when the price is so high and the use
so common. Indeed, the high price itself—$10 000 per
ampoule—might help to convince clinicians that it the drug is
effective.
The need for clarity
Clearly, clinicians might both believe it to be true that rVIIa
works and desperately need it to be true that the drug contributes
to haemostasis in all situations. Anyone wishing to promote
adherence to evidence in this context thus needs to contend with
both genuine uncertainty and the powerful force of desperation.
In desperate situations, anecdote and experience often assume
greater salience than statistics. The rules of evidence based
medicine might therefore be overridden by urgency and the
demands of context.
An apparently irreducible tension exists between appeals to
weak evidence, clinical observation, mechanism, and desperate
need on the one hand, and appeals to hard (albeit imperfect)
evidence on the other. And, in this, rFVIIa is not unique—take,
for example, the non-evidence based use of high dose adrenaline
during resuscitation efforts.20 There is no simple solution to this
quandary. While it would be easy to dismiss, and insist on
stopping, non-evidence based use of rFVIIa on the grounds that
it does not reduce overall mortality, we cannot ignore the many
compelling reasons for its ongoing use. Nor can we ignore the
fact that the existing evidence from systematic reviews does not
prove that rFVIIa is completely ineffective in reducing bleeding
in all patients. What is needed, therefore, is for clinical leaders
and policymakers to further clarify the range of outcomes that
might result from the administration of rVIIa (relating to both
harms and benefits), what outcomes matter, how much we are
prepared to pay for those outcomes, and what we should do
until these issues are resolved.
Situations like this take us to the edges of evidence based
medicine. The community needs to be reassured that doctors
prescribe medicines on the basis of clear evidence about
efficacy, safety, and cost effectiveness—particularly in relation
to high cost drugs, which are inevitably associated with an
opportunity cost. But in cases like that of rFVIIa, such
information is lacking or contested. In these situations, there is
little to be gained by determining who is right and who is
wrong—or threatening legal sanctions against those who choose
a particular course of action. It is more important to ensure that
clinical decisions can be understood, explained, and justified
so that any untoward outcomes can be predicted and managed.
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